Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 595-major-skin-disorders-with-mcc
    Ask Trek AI about this page

    Major Skin Disorders with MCC: Inpatient Reimbursement Overview

    DRG 595 encompasses major skin disorders with a Major Complication or Comorbidity, reflecting high-acuity dermatologic and soft-tissue conditions that require intensive inpatient care. It matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity increases resource use and influences Medicare payment under the inpatient prospective payment system.

    Customize your policy alerts

    Sign up for drg 595 policy alerts

    Get alerted when payer policies referencing 595 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 595 Overview

    DRG 595 covers major skin disorders with Major Complication or Comorbidity, including severe infections, extensive burns, necrotizing soft tissue infections, and other complex dermatologic conditions requiring significant inpatient resources. This Diagnosis-Related Group captures cases with higher clinical severity and resource use due to the presence of a Major Complication or Comorbidity, which influences Medicare payment under inpatient prospective payment systems. Accurate clinical documentation and coding of the underlying skin condition and the Major Complication or Comorbidity are central to appropriate claim assignment and reimbursement. Understanding the scope of DRG 595 is important for hospitals managing high-acuity dermatologic and soft-tissue surgical patients.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute immunomodulatory or wound-management intervention trials: randomized or open-label studies testing short-term hospital-based interventions such as systemic immunomodulators, biologic agents widely referenced in dermatology, or novel topical/advanced wound dressings for severe inflammatory or necrotizing skin disorders. These trials enroll inpatients with major skin disorders complicated by life-threatening features or organ dysfunction (for example extensive blistering diseases, severe drug eruptions, or infected necrotic skin) to evaluate rapid control of inflammation, prevention of sepsis, or acceleration of wound closure. Results inform inpatient clinical pathways, resource needs (ICU vs ward care), and short-term utilization metrics that matter to providers and payers for DRG 595 cost and length-of-stay management.
    • Comparative effectiveness studies of debridement, grafting, and critical-care adjuncts: pragmatic or observational studies comparing surgical and supportive care strategies (timing and extent of debridement, use of biologic versus autologous skin grafting approaches, negative-pressure wound therapy, and protocols for nutritional/vascular support) in hospitalized patients with extensive skin loss or necrosis. These studies target patients with differing comorbidity burdens and multiple complications (the MCC element), assessing outcomes such as time to wound closure, need for repeat procedures, infection rates, and inpatient resource utilization. Findings help clinicians choose cost-effective procedural pathways and help payers understand drivers of readmission and high-cost resource use under DRG 595.
    • Post-discharge outcomes and care-transition research: prospective cohort or health-services research examining readmission rates, outpatient wound care adherence, functional recovery, and long-term quality-of-life after hospital discharge for patients treated for major skin disorders with significant comorbidities. These studies follow diverse discharge dispositions (home with home health, skilled nursing facility, or long-term acute care) to identify predictors of rehospitalization, durable disability, and durable medical equipment or home health needs. Results guide discharge planning, bundled-payment models, and payer strategies to reduce avoidable readmissions and optimize post-acute resource allocation for this high-risk DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.